%PDF-1.5
%âãÏÓ
1 0 obj<>
endobj
2 0 obj<>
endobj
3 0 obj<>
endobj
5 0 obj null
endobj
6 0 obj<>
endobj
7 0 obj<>
endobj
8 0 obj<>>>
endobj
9 0 obj<>
endobj
10 0 obj<>]/C/SpdrArt/P 9 0 R/S/Article/Pg 11 0 R>>
endobj
11 0 obj<>/ProcSet[/PDF/Text]>>/StructParents 0>>
endobj
12 0 obj<>/Subtype/Link/A<>>>
endobj
13 0 obj<>/Font<>>>/DA(/Helv 0 Tf 0 g )>>
endobj
14 0 obj<>
endobj
15 0 obj<>
endobj
16 0 obj<>
endobj
17 0 obj[12 0 R 20 0 R 21 0 R 22 0 R]
endobj
18 0 obj<>
endobj
19 0 obj[10 0 R]
endobj
20 0 obj<>/Subtype/Link/A<>>>
endobj
21 0 obj<>/Subtype/Link/A<>>>
endobj
22 0 obj<>/Subtype/Link/A<>>>
endobj
23 0 obj<>/ProcSet[/PDF/Text]>>/StructParents 1>>
endobj
24 0 obj[10 0 R]
endobj
25 0 obj<>/Subtype/Link/A<>>>
endobj
26 0 obj[25 0 R]
endobj
27 0 obj<>
endobj
28 0 obj<>
endobj
29 0 obj<>
endobj
30 0 obj<>
endobj
31 0 obj<>
endobj
32 0 obj 9368
endobj
33 0 obj<>stream
/Artifact <>BDC
0 0 0 rg
0 i
BT
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 9 0 0 9 18 780.17 Tm
(HIVInfo.us - Lexiva - fosamprenavir information)Tj
ET
EMC
/WebCaptureBG BMC
/WebCaptureFN <>BDC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
10 766 m
501.422 766 l
500.422 765 l
11 765 l
h
f
10 766 m
10 694.39999 l
11 695.39999 l
11 765 l
h
f
501.422 766 m
501.422 694.39999 l
500.422 695.39999 l
500.422 765 l
h
f
10 694.39999 m
501.422 694.39999 l
500.422 695.39999 l
11 695.39999 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
0 0.50197 0 rg
16 733.2 479.422 26.8 re
f
0 0 0 rg
15 761 m
496.422 761 l
495.422 760 l
16 760 l
h
f
15 761 m
15 732.2 l
16 733.2 l
16 760 l
h
f
496.422 761 m
496.422 732.2 l
495.422 733.2 l
495.422 760 l
h
f
15 732.2 m
496.422 732.2 l
495.422 733.2 l
16 733.2 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
1 1 1 rg
16 700.39999 479.422 26.8 re
f
0 0 0 rg
15 728.2 m
496.422 728.2 l
495.422 727.2 l
16 727.2 l
h
f
15 728.2 m
15 699.39999 l
16 700.39999 l
16 727.2 l
h
f
496.422 728.2 m
496.422 699.39999 l
495.422 700.39999 l
495.422 727.2 l
h
f
15 699.39999 m
496.422 699.39999 l
495.422 700.39999 l
16 700.39999 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
0.06667 0.06667 0.06667 rg
10 680.39999 m
602 680.39999 l
599 677.39999 l
13 677.39999 l
h
f
10 680.39999 m
10 36 l
13 36 l
13 677.39999 l
h
f
602 680.39999 m
602 36 l
599 36 l
599 677.39999 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
0.50197 0 0.50197 rg
18 643.39999 576 29 re
f
0.06667 0.06667 0.06667 rg
17 673.39999 m
595 673.39999 l
594 672.39999 l
18 672.39999 l
h
f
17 673.39999 m
17 642.39999 l
18 643.39999 l
18 672.39999 l
h
f
595 673.39999 m
595 642.39999 l
594 643.39999 l
594 672.39999 l
h
f
17 642.39999 m
595 642.39999 l
594 643.39999 l
18 643.39999 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 638.39999 m
124.625 638.39999 l
123.625 637.39999 l
18 637.39999 l
h
f
17 638.39999 m
17 592.39999 l
18 593.39999 l
18 637.39999 l
h
f
124.625 638.39999 m
124.625 592.39999 l
123.625 593.39999 l
123.625 637.39999 l
h
f
17 592.39999 m
124.625 592.39999 l
123.625 593.39999 l
18 593.39999 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
128.625 638.39999 m
595 638.39999 l
594 637.39999 l
129.625 637.39999 l
h
f
128.625 638.39999 m
128.625 592.39999 l
129.625 593.39999 l
129.625 637.39999 l
h
f
595 638.39999 m
595 592.39999 l
594 593.39999 l
594 637.39999 l
h
f
128.625 592.39999 m
595 592.39999 l
594 593.39999 l
129.625 593.39999 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 588.39999 m
124.625 588.39999 l
123.625 587.39999 l
18 587.39999 l
h
f
17 588.39999 m
17 496.29231 l
18 497.29231 l
18 587.39999 l
h
f
124.625 588.39999 m
124.625 496.29231 l
123.625 497.29231 l
123.625 587.39999 l
h
f
17 496.29231 m
124.625 496.29231 l
123.625 497.29231 l
18 497.29231 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
128.625 588.39999 m
595 588.39999 l
594 587.39999 l
129.625 587.39999 l
h
f
128.625 588.39999 m
128.625 496.29231 l
129.625 497.29231 l
129.625 587.39999 l
h
f
595 588.39999 m
595 496.29231 l
594 497.29231 l
594 587.39999 l
h
f
128.625 496.29231 m
595 496.29231 l
594 497.29231 l
129.625 497.29231 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 492.29231 m
124.625 492.29231 l
123.625 491.29231 l
18 491.29231 l
h
f
17 492.29231 m
17 334.66154 l
18 335.66154 l
18 491.29231 l
h
f
124.625 492.29231 m
124.625 334.66154 l
123.625 335.66154 l
123.625 491.29231 l
h
f
17 334.66154 m
124.625 334.66154 l
123.625 335.66154 l
18 335.66154 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
128.625 492.29231 m
595 492.29231 l
594 491.29231 l
129.625 491.29231 l
h
f
128.625 492.29231 m
128.625 334.66154 l
129.625 335.66154 l
129.625 491.29231 l
h
f
595 492.29231 m
595 334.66154 l
594 335.66154 l
594 491.29231 l
h
f
128.625 334.66154 m
595 334.66154 l
594 335.66154 l
129.625 335.66154 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 330.66154 m
124.625 330.66154 l
123.625 329.66154 l
18 329.66154 l
h
f
17 330.66154 m
17 45.19969 l
18 46.19969 l
18 329.66154 l
h
f
124.625 330.66154 m
124.625 45.19969 l
123.625 46.19969 l
123.625 329.66154 l
h
f
17 45.19969 m
124.625 45.19969 l
123.625 46.19969 l
18 46.19969 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
128.625 330.66154 m
595 330.66154 l
594 329.66154 l
129.625 329.66154 l
h
f
128.625 330.66154 m
128.625 45.19969 l
129.625 46.19969 l
129.625 329.66154 l
h
f
595 330.66154 m
595 45.19969 l
594 46.19969 l
594 329.66154 l
h
f
128.625 45.19969 m
595 45.19969 l
594 46.19969 l
129.625 46.19969 l
h
f
EMC
EMC
EMC
/Article <>BDC
q
0 18 612 756 re
W* n
1 1 1 rg
BT
/TT0 1 Tf
14 0 0 14 20 744.39798 Tm
(HIVInfo.us )Tj
10.76923 0 0 10.76923 93.12199 744.39798 Tm
(presents)Tj
0 0 0 rg
14 0 0 14 20 711.59798 Tm
(An HIV Information Site & HIV Educational Resource Site \(HIS & HERS\))Tj
1 1 1 rg
17.5 0 0 17.5 22 653.89748 Tm
(Lexiva - fosamprenavir)Tj
0 0 0 rg
15 0 0 15 22 620.96927 Tm
(General )Tj
0 -1.2 TD
(Information)Tj
/TT1 1 Tf
12.5 0 0 12.5 133.625 619.70221 Tm
(This drug is almost always used as one component of a multidrug combinat\
ion to )Tj
T*
(suppress the human immunodeficiency \(HIV\) viral load.)Tj
/TT0 1 Tf
15 0 0 15 22 538.91542 Tm
(Specifics)Tj
/TT1 1 Tf
12.92308 0 0 12.92308 133.625 572.34013 Tm
(Fosamprenavir is one of the newest antiviral drugs against HIV, but it i\
s rapidly )Tj
0 -1.26631 TD
(establishing itself as a potent, convenient, and very well-tolerated opt\
ion.)Tj
/T1_0 1 Tf
14 0 0 14 548.80469 555.97556 Tm
( )Tj
/TT1 1 Tf
12.92308 0 0 12.92308 133.625 521.24783 Tm
(Fosamprenavir works by inhibiting the production of HIV's proteins. It \
is )Tj
0 -1.2 TD
(classified as a protease inhibitor \(PI\).)Tj
/TT0 1 Tf
15 0 0 15 22 410.04619 Tm
(Dosing)Tj
/TT1 1 Tf
12.92308 0 0 12.92308 133.625 476.23245 Tm
(Generally fosamprenavir is taken as one of the 700 mg pills twice a day \
with or )Tj
0 -1.26631 TD
(without food. Usually it is taken with 100 mg of ritonavir \(Norvir\) t\
wice a day.)Tj
/T1_0 1 Tf
14 0 0 14 570.28285 459.86786 Tm
( )Tj
/TT1 1 Tf
12.92308 0 0 12.92308 133.625 425.14014 Tm
(Occasionally fosamprenavir may be taken as a single daily dose of two 70\
0 mg )Tj
0 -1.2 TD
(pills with two 100 mg ritonavir \(Norvir\) gel caps.)Tj
0 -2.67024 TD
(This combination of ritonavir and fosamprenavir is termed "boosted )Tj
0 -1.2 TD
(fosamprenavir" because ritonavir increases the levels of fosamprenavir i\
n the )Tj
T*
(bloodstream. )Tj
/TT0 1 Tf
14 0 0 14 22 310.59811 Tm
(Adherence)Tj
18.75 0 0 18.75 94.35201 310.59811 Tm
( )Tj
/TT1 1 Tf
12.5 0 0 12.5 22 293.41376 Tm
(\(this refers to )Tj
T*
(your willingness, )Tj
T*
(ability, and )Tj
T*
(actual )Tj
T*
(performance in )Tj
T*
(taking your )Tj
0 -1.29413 TD
(medications\))Tj
/T1_0 1 Tf
14 0 0 14 92.85001 202.23709 Tm
( )Tj
/TT1 1 Tf
12.92308 0 0 12.92308 22 167.55168 Tm
(For further )Tj
0 -1.2 TD
(information and )Tj
T*
(tips on )Tj
T*
(adherence, go )Tj
T*
(to the )Tj
0.50197 0 0.50197 rg
/TT0 1 Tf
0 -1.1729 TD
(Adherence )Tj
0 -1.38187 TD
(section)Tj
0 0 0 rg
/TT1 1 Tf
( of this )Tj
T*
(site.)Tj
/TT0 1 Tf
12.5 0 0 12.5 133.625 297.32936 Tm
(As with any antiviral drug or antibiotic, try not to ever miss a dose.)Tj
/TT1 1 Tf
( If you )Tj
0 -1.22711 TD
(miss a dose and notice that you have done so within a few hours of its s\
cheduled )Tj
0 -1.29413 TD
(time, you may take the dose as usual and take the next dose at its regul\
ar time. )Tj
/T1_0 1 Tf
14 0 0 14 576.21249 265.81386 Tm
( )Tj
/TT1 1 Tf
12.92308 0 0 12.92308 133.625 231.12845 Tm
(It is very important that you do not alter the dosing of fosamprenavir o\
r ritonavir )Tj
0 -1.2 TD
(without advice from your healthcare provider.)Tj
12.5 0 0 12.5 391.46623 215.62076 Tm
( )Tj
/TT0 1 Tf
-20.6273 -2.70454 Td
(If you miss more than one dose, look at the reasons why you missed them \
)Tj
0 -1.22711 TD
(and come up with a plan to avoid it in the future.)Tj
/TT1 1 Tf
( For example, if you fell )Tj
T*
(asleep too early, take the medicine earlier in the evening, with your la\
ter meal, set )Tj
0 -1.2 TD
(an alarm, or have someone appointed to wake you up for your medicine. \
)Tj
0 -2.72 TD
(It is strongly recommended that you consider using weekly pill boxes and\
arrange )Tj
0 -1.2 TD
(all of your doses a week in advance. Buy a small pill box so that you c\
an carry a )Tj
T*
(dose or two of your medicines with you in case you are away from home.)Tj
ET
EMC
/Artifact <>BDC
Q
0 0 0 rg
BT
/T1_0 1 Tf
9 0 0 9 18 7.17 Tm
(http://hivinfo.us/fosamprenavir.html \(1 of 2\)1/16/2005 12:27:17 PM)Tj
ET
EMC
endstream
endobj
34 0 obj 6628
endobj
35 0 obj<>stream
/Artifact <>BDC
0 0 0 rg
0 i
BT
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 9 0 0 9 18 780.17 Tm
(HIVInfo.us - Lexiva - fosamprenavir information)Tj
ET
EMC
/WebCaptureBG BMC
/WebCaptureFN <>BDC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
0.06667 0.06667 0.06667 rg
10 766 m
10 74.65079 l
13 77.65079 l
13 766 l
h
f
602 766 m
602 74.65079 l
599 77.65079 l
599 766 l
h
f
10 74.65079 m
602 74.65079 l
599 77.65079 l
13 77.65079 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 762 m
124.625 762 l
123.625 761 l
18 761 l
h
f
17 762 m
17 483.38461 l
18 484.38461 l
18 761 l
h
f
124.625 762 m
124.625 483.38461 l
123.625 484.38461 l
123.625 761 l
h
f
17 483.38461 m
124.625 483.38461 l
123.625 484.38461 l
18 484.38461 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
128.625 762 m
595 762 l
594 761 l
129.625 761 l
h
f
128.625 762 m
128.625 483.38461 l
129.625 484.38461 l
129.625 761 l
h
f
595 762 m
595 483.38461 l
594 484.38461 l
594 761 l
h
f
128.625 483.38461 m
595 483.38461 l
594 484.38461 l
129.625 484.38461 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 479.38461 m
124.625 479.38461 l
123.625 478.38461 l
18 478.38461 l
h
f
17 479.38461 m
17 195.41539 l
18 196.41539 l
18 478.38461 l
h
f
124.625 479.38461 m
124.625 195.41539 l
123.625 196.41539 l
123.625 478.38461 l
h
f
17 195.41539 m
124.625 195.41539 l
123.625 196.41539 l
18 196.41539 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
128.625 479.38461 m
595 479.38461 l
594 478.38461 l
129.625 478.38461 l
h
f
128.625 479.38461 m
128.625 195.41539 l
129.625 196.41539 l
129.625 478.38461 l
h
f
595 479.38461 m
595 195.41539 l
594 196.41539 l
594 478.38461 l
h
f
128.625 195.41539 m
595 195.41539 l
594 196.41539 l
129.625 196.41539 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 191.41539 m
595 191.41539 l
594 190.41539 l
18 190.41539 l
h
f
17 191.41539 m
17 113.50877 l
18 114.50877 l
18 190.41539 l
h
f
595 191.41539 m
595 113.50877 l
594 114.50877 l
594 190.41539 l
h
f
17 113.50877 m
595 113.50877 l
594 114.50877 l
18 114.50877 l
h
f
EMC
q
0 18 612 756 re
W* n
/Artifact <>BDC
Q
17 109.50877 m
595 109.50877 l
594 108.50877 l
18 108.50877 l
h
f
17 109.50877 m
17 81.65079 l
18 82.65079 l
18 108.50877 l
h
f
595 109.50877 m
595 81.65079 l
594 82.65079 l
594 108.50877 l
h
f
17 81.65079 m
595 81.65079 l
594 82.65079 l
18 82.65079 l
h
f
EMC
EMC
EMC
/Article <>BDC
q
0 18 612 756 re
W* n
0 0 0 rg
BT
/TT0 1 Tf
15 0 0 15 22 744.56926 Tm
(Possible )Tj
0 -1.2 TD
(Side Effects)Tj
/TT1 1 Tf
12.92308 0 0 12.92308 22 709.94014 Tm
(The package )Tj
T*
(insert for most )Tj
T*
(drugs including )Tj
T*
(fosamprenavir )Tj
T*
(is often )Tj
T*
(overwhelming )Tj
T*
(and scary with )Tj
T*
(perhaps an )Tj
T*
(overemphasis )Tj
T*
(on side effects. )Tj
T*
(We have )Tj
T*
(summarized the )Tj
T*
(important and )Tj
T*
(more common )Tj
T*
(problems here.)Tj
/TT0 1 Tf
12.5 0 0 12.5 133.625 746.59489 Tm
(Most people take fosamprenavir without many side effects. )Tj
/TT1 1 Tf
0 -2.74712 TD
(Possible side effects include stomach upset, diarrhea, nausea, liver pro\
blems, )Tj
0 -1.2 TD
(increased fat \(cholesterol and triglycerides\) in the blood, and possib\
ly diabetes. )Tj
T*
(Usually you will have blood tests done in the first month to look for th\
e beneficial )Tj
T*
(effects of fosamprenavir and any side effects. )Tj
12.92308 0 0 12.92308 133.625 632.89398 Tm
(Many minor side effects will either stay constant or get better with tim\
e. It is )Tj
T*
(mainly the side effects that are severe or get worse that may cause sign\
ificant )Tj
T*
(health risks for you.)Tj
12.5 0 0 12.5 133.625 567.73299 Tm
(All drugs of this type can cause or contribute to abnormal fat redistrib\
ution )Tj
T*
(characterized by an enlarged belly and/or thinning of the face, arms, or\
legs. In )Tj
T*
(most cases this would be also accompanied by elevated cholesterol levels\
, )Tj
T*
(elevated triglyceride levels, and perhaps a tendency to develop diabetes\
. )Tj
T*
(Fosamprenavir may have less effect on these problems than other protease\
)Tj
T*
(inhibitors.)Tj
/TT0 1 Tf
15 0 0 15 22 403.75388 Tm
(Interactions)Tj
/TT1 1 Tf
12.92308 0 0 12.92308 22 387.12476 Tm
(This refers to )Tj
T*
(the way that )Tj
T*
(fosamprenavir )Tj
T*
(affects other )Tj
T*
(medications )Tj
T*
(and how other )Tj
T*
(medications )Tj
T*
(affect )Tj
T*
(fosamprenavir)Tj
/TT0 1 Tf
8.63765 15.52353 Td
(Fosamprenavir levels in the bloodstream are affected by the following )Tj
T*
(drugs and should be used cautiously if at all:)Tj
/TT1 1 Tf
0 -1.2271 TD
(Efavirenz \(Sustiva\))Tj
0 -1.2 TD
(Lopinavir/ritonavir \(Kaletra\))Tj
T*
(Delavirdine \(Rescriptor\))Tj
/TT0 1 Tf
0 -2.1729 TD
(Fosamprenavir affects the levels of certain drugs in the bloodstream and\
)Tj
0 -1.2 TD
(these drugs should be used cautiously - usually with dose adjustments:)Tj
/TT1 1 Tf
0 -1.22711 TD
(Atorvastatin \(Lipitor\))Tj
0 -1.2 TD
(Methadone \(Dolophine and others\))Tj
T*
(Rifabutin \(Mycobutin\))Tj
1 0 0 rg
/TT0 1 Tf
0 -2.1729 TD
(The following drugs should not be taken with fosamprenavir:)Tj
0 0 0 rg
/TT1 1 Tf
0 -1.22711 TD
(Ergot derivatives: dihydroergotamin, ergonovine, ergotamine, methylergon\
ovine)Tj
0 -1.2 TD
(GI motility agent: cisapride)Tj
T*
(Neuroleptic: pimozide)Tj
T*
(Sedatives/sleeping pills: midazolam, triazolam)Tj
T*
(Anti-TB drug: rifampin)Tj
1 0 0 rg
/TT0 1 Tf
15 0 0 15 22 173.57805 Tm
(Report to you healthcare provider or go to an Emergency Room)Tj
/TT1 1 Tf
( )Tj
0 0 0 rg
13.75 0 0 13.75 480.42999 173.57805 Tm
(if you have )Tj
-33.34036 -1.26086 Td
(severe side effects, increasing side effects, shortness of breath, uncon\
trollable diarrhea, )Tj
T*
(fever, weakness, jaundice \(eyes and skin turn yellow,\) muscle pain, na\
usea and vomiting so )Tj
T*
(that you cannot hold down your food and liquids.)Tj
12.92308 0 0 12.92308 22 93.44891 Tm
(You can download this handout in PDF format by clicking )Tj
0.50197 0 0.50197 rg
/TT0 1 Tf
(HERE)Tj
0 0 0 rg
/TT1 1 Tf
(.)Tj
10 0 0 10 10 47.09256 Tm
(1.16.2005)Tj
ET
EMC
/Artifact <>BDC
Q
0 0 0 rg
BT
/T1_0 1 Tf
9 0 0 9 18 7.17 Tm
(http://hivinfo.us/fosamprenavir.html \(2 of 2\)1/16/2005 12:27:17 PM)Tj
ET
EMC
endstream
endobj
36 0 obj(HIVInfo.us - Lexiva - fosamprenavir information)
endobj
37 0 obj<>
endobj
38 0 obj<>
endobj
39 0 obj<>
endobj
40 0 obj<>
endobj
41 0 obj[38 0 R]
endobj
42 0 obj(http://hivinfo.us/fosamprenavir.html)
endobj
43 0 obj(œö×Wp…¹+·ÖÄ°X)
endobj
44 0 obj<>
endobj
45 0 obj<>
endobj
46 0 obj(‚æ'…¤ÇÙs3ùsAŠk)
endobj
47 0 obj<>
endobj
48 0 obj<>
endobj
49 0 obj<>
endobj
50 0 obj<>
endobj
51 0 obj<>
endobj
52 0 obj<>stream
HIVInfo.us - Lexiva - fosamprenavir information
endstream
endobj
xref
0 53
0000000004 65535 f
0000000016 00000 n
0000000159 00000 n
0000000217 00000 n
0000000000 00001 f
0000000390 00000 n
0000000410 00000 n
0000000476 00000 n
0000000576 00000 n
0000000620 00000 n
0000000667 00000 n
0000000760 00000 n
0000000965 00000 n
0000001128 00000 n
0000001252 00000 n
0000001328 00000 n
0000001417 00000 n
0000002608 00000 n
0000002653 00000 n
0000002697 00000 n
0000002721 00000 n
0000002894 00000 n
0000003059 00000 n
0000003224 00000 n
0000003429 00000 n
0000003453 00000 n
0000003629 00000 n
0000003653 00000 n
0000003743 00000 n
0000004920 00000 n
0000005094 00000 n
0000006267 00000 n
0000006435 00000 n
0000006456 00000 n
0000015877 00000 n
0000015898 00000 n
0000022579 00000 n
0000022644 00000 n
0000022680 00000 n
0000022751 00000 n
0000022780 00000 n
0000022889 00000 n
0000022913 00000 n
0000022967 00000 n
0000023001 00000 n
0000023119 00000 n
0000023170 00000 n
0000023204 00000 n
0000023247 00000 n
0000023288 00000 n
0000023329 00000 n
0000023413 00000 n
0000023540 00000 n
trailer
<]>>
startxref
26886
%%EOF
1 0 obj<>/StructTreeRoot 7 0 R/Metadata 54 0 R/SpiderInfo 37 0 R>>
endobj
3 0 obj<>
endobj
53 0 obj null
endobj
54 0 obj<>stream
HIVInfo.us - Lexiva - fosamprenavir informationHIVInfo.us - Lexiva - fosamprenavir informationHIVInfo.us
endstream
endobj
xref
1 1
0000028101 00000 n
3 1
0000028287 00000 n
53 2
0000028594 00000 n
0000028615 00000 n
trailer
<<09c8be6cb69d3a4d8350a61264a5239b>]/Prev 26886 >>
startxref
32232
%%EOF